Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated, PD-L1-positive, Advanced TNBC By Ogkologos - January 30, 2026 153 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ASCENT-04/KEYNOTE-D19 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Nivolumab with Chemotherapy for Previously Untreated Hodgkin Lymphoma 2026 ESMO Breast Cancer Award Recipient Announced Solid Organ Transplant Recipients with Pretransplant Cancer Have an Elevated Risk of Posttransplant Cancer of the Same Cancer Type MOST POPULAR Happy Nurses Month! May 3, 2021 EMA Recommends Extending Indications for Pembrolizumab to Include Adjuvant Treatment in... October 6, 2023 FDA Approves Revumenib for Relapsed or Refractory Acute Leukaemia with a... December 10, 2024 Concurrent Chemoradiotherapy Followed by Adjuvant Cisplatin-Gemcitabine for the Treatment of Patients... June 15, 2023 Load more HOT NEWS Understanding Serving Sizes ΚΑΡΚΙΝΟΣ ΤΟΥ ΠΡΟΣΤΑΤΗ FDA Approves First Comprehensive Pan-Tumour Liquid Biopsy Test for Patients with... New targeted lung cancer screening programme on the horizon
